NioCorp and Atossa Therapeutics to Feature on Bloomberg TV, Highlighting Strategic Developments

What's Happening?

NioCorp Developments Ltd. and Atossa Therapeutics, Inc. are set to appear on the RedChip Small Stocks, Big Money show, airing on Bloomberg TV. NioCorp's CEO, Mark Smith, will discuss the Elk Creek Project in Nebraska, a significant critical minerals mine poised to produce niobium, scandium, and titanium. This project is backed by substantial support, including a U.S. Department of Defense grant and an $800 million U.S. Export-Import Bank debt financing application. Atossa Therapeutics, led by CEO Dr. Steven Quay, will present its advancements in breast cancer treatment, focusing on its lead clinical candidate, (Z)-endoxifen. This next-generation SERM is undergoing multiple Phase 2 studies, showing promise in metastatic breast cancer treatment. Both companies aim to deliver long-term value for shareholders through their innovative projects.

Why It's Important?

The developments discussed by NioCorp and Atossa Therapeutics are significant for U.S. industries and public health. NioCorp's Elk Creek Project could establish a domestic supply chain for critical minerals, essential for clean energy, aerospace, and defense sectors, reducing reliance on foreign sources. Atossa's advancements in breast cancer treatment could revolutionize patient care, offering new hope for those with metastatic breast cancer. These initiatives not only promise economic benefits but also align with national interests in securing critical resources and advancing healthcare solutions.

What's Next?

NioCorp is advancing towards the construction phase of the Elk Creek Project, with all major permits secured and significant offtake agreements in place. Atossa Therapeutics is progressing with its clinical trials, aiming to achieve further milestones in its drug development pipeline. Both companies are expected to continue engaging with investors and stakeholders to secure additional support and funding, ensuring the successful implementation of their strategic goals.

Beyond the Headlines

The projects by NioCorp and Atossa Therapeutics highlight broader trends in the U.S. towards self-sufficiency in critical minerals and innovation in healthcare. NioCorp's project could lead to a shift in the global supply chain dynamics, while Atossa's research underscores the importance of investing in next-generation medical treatments. These efforts reflect a growing emphasis on sustainable and strategic development in key sectors.